Trial reportThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2011
Depression in Parkinson's disease: symptom improvement and residual symptoms after acute pharmacologic management.
Trial report in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Efficacy and tolerability of antidepressants in individuals suffering from physical conditions and depressive disorders: network meta-analysis.The British journal of psychiatry : the journal of mental science · 2025Pooled it
- A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.Sleep medicine reviews · 2017Pooled it
- Serum sirtuin 3 levels and multimodal abnormalities in brain structure and function in Parkinson's disease patients with depression.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2025Article
- Active constituents of saffron (Experimental and therapeutic medicine · 2023Review
- Parkinson and depression: review and outlook.Journal of neural transmission (Vienna, Austria : 1996) · 2022Review
- The Treatment of Sleep Dysfunction in Neurodegenerative Disorders.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2021Review
- Drug Choices and Advancements for Managing Depression in Parkinson's Disease.Current neuropharmacology · 2020Review
- Dopaminergic Lesion in the Olfactory Bulb Restores Olfaction and Induces Depressive-Like Behaviors in a 6-OHDA Model of Parkinson's Disease.Molecular neurobiology · 2019Article
- Glycyrrhizic Acid Alleviates 6-Hydroxydopamine and Corticosterone-Induced Neurotoxicity in SH-SY5Y Cells Through Modulating Autophagy.Neurochemical research · 2018Article
- Disturbances of Sleep and Alertness in Parkinson's Disease.Current neurology and neuroscience reports · 2018Review
- Rational pharmacological approaches for cognitive dysfunction and depression in Parkinson's disease.Frontiers in neurology · 2015Review
- Monoamine reuptake inhibitors in Parkinson's disease.Parkinson's disease · 2015Review
- Psychiatric issues in cognitive impairment.Movement disorders : official journal of the Movement Disorder Society · 2014Review
- Treatment of the sleep disorders associated with Parkinson's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2014Review
- Depression and Parkinson's disease: current knowledge.Current neurology and neuroscience reports · 2013Review
- Parkinson's disease therapeutics: new developments and challenges since the introduction of levodopa.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Review
- Nonmotor symptoms in Parkinson's disease in 2012: relevant clinical aspects.Parkinson's disease · 2012Article
- Impact of anxiety on quality of life in Parkinson's disease.Parkinson's disease · 2012Article
- Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.Therapeutic advances in neurological disorders · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
objectiveParkinson's disease (PD) is frequently complicated by depression and there is a paucity of controlled research that can inform the management of this disabling nonmotor complaint. A randomized controlled trial of nortriptyline, paroxetine, and placebo for the treatment of depression in PD (dPD) was recently completed. The purpose of this article is to describe the baseline pattern of depressive symptom presentation in PD, the specific symptoms of dPD that improve with pharmacotherapy, and the residual symptoms that remain in patients who meet a priori criteria for response or remission after acute treatment (8 weeks).
settingThe Departments of Psychiatry and Neurology at Robert Wood Johnson Medical School, New Jersey.
participants: Fifty-two depressed patients (major depression or dysthymia based on Diagnostic and Statistical Manual of Mental Disorders 4th edition criteria) with Parkinson's disease (by research criteria). DESIGN/
interventionA randomized controlled trial of nortriptyline, paroxetine, and placebo. MEASUREMENT: The four subscales (core mood, anxiety, insomnia, and somatic) and individual items from the Hamilton Rating Scale for Depression-17 were the focus of this study. These measures were assessed at baseline and Week 8.
resultsBaseline depressive symptoms were unrelated to motor functioning. Treatment response was associated with significant improvements in the core mood, anxiety, insomnia, and somatic symptoms seen in dPD. Residual symptoms, such as sadness and loss of interest, persisted in treatment responders in a milder form than was initially present.
conclusionsAntidepressants may influence all symptoms of dPD, including those that share great overlap with the physical disease process. Additional research regarding adjunctive interventions is needed to help optimize the management of dPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.